GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Citius Oncology Inc (NAS:CTOR) » Definitions » Cash Ratio

CTOR (Citius Oncology) Cash Ratio : 0.00 (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Citius Oncology Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Citius Oncology's Cash Ratio for the quarter that ended in Sep. 2024 was 0.00.

Citius Oncology has a Cash Ratio of 0.00. It indicates that there are more current liabilities than Cash, Cash Equivalents, Marketable Securities, and the company does not have sufficient cash on hand to pay off its short-term debt.

The historical rank and industry rank for Citius Oncology's Cash Ratio or its related term are showing as below:

CTOR's Cash Ratio is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.59
* Ranked among companies with meaningful Cash Ratio only.

Citius Oncology Cash Ratio Historical Data

The historical data trend for Citius Oncology's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Citius Oncology Cash Ratio Chart

Citius Oncology Annual Data
Trend Sep22 Sep23 Sep24
Cash Ratio
- - -

Citius Oncology Semi-Annual Data
Sep22 Sep23 Sep24
Cash Ratio - - -

Competitive Comparison of Citius Oncology's Cash Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Citius Oncology's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Citius Oncology's Cash Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Citius Oncology's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Citius Oncology's Cash Ratio falls into.


;
;

Citius Oncology Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Citius Oncology's Cash Ratio for the fiscal year that ended in Sep. 2024 is calculated as:

Citius Oncology's Cash Ratio for the quarter that ended in Sep. 2024 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Citius Oncology  (NAS:CTOR) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Citius Oncology Cash Ratio Related Terms

Thank you for viewing the detailed overview of Citius Oncology's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Citius Oncology Business Description

Traded in Other Exchanges
N/A
Address
11 Commerce Drive, First Floor, Cranford, NY, USA, 07016
Citius Oncology Inc is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products targeting unmet needs with a focus on oncology products. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids.